MB Levis & Associates LLC Has $214,000 Holdings in Pfizer Inc. (NYSE:PFE)

MB Levis & Associates LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 76.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,432 shares of the biopharmaceutical company’s stock after acquiring an additional 3,647 shares during the period. MB Levis & Associates LLC’s holdings in Pfizer were worth $214,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. William B. Walkup & Associates Inc. grew its position in Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 454 shares during the last quarter. Members Trust Co lifted its stake in shares of Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 467 shares during the period. Sutton Place Investors LLC grew its position in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 472 shares in the last quarter. Bellevue Group AG increased its stake in Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock valued at $3,756,000 after acquiring an additional 485 shares during the period. Finally, Gould Capital LLC raised its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $24.33 on Tuesday. The business has a fifty day moving average of $24.32 and a 200-day moving average of $24.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm has a market cap of $138.33 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company’s revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.82 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.07%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Analysts Set New Price Targets

PFE has been the topic of several recent research reports. Morgan Stanley lifted their price objective on Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 30th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group increased their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Finally, BMO Capital Markets decreased their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.